Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Hansen KE, et al. Among authors: litman hj. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022. Ther Adv Musculoskelet Dis. 2022. PMID: 36601090 Free PMC article.
Patterns in the sequential treatment of rheumatoid arthritis patients starting a b/tsDMARD: 10-year experience from a US-based registry.
Matsson A, Solomon DH, Crabtree MM, Harrison RW, Litman HJ, Johansson FD. Matsson A, et al. Among authors: litman hj. Res Sq [Preprint]. 2023 Feb 27:rs.3.rs-2624931. doi: 10.21203/rs.3.rs-2624931/v1. Res Sq. 2023. Update in: ACR Open Rheumatol. 2024 Jan;6(1):5-13. doi: 10.1002/acr2.11621 PMID: 36909600 Free PMC article. Updated. Preprint.
Patterns in the Sequential Treatment of Patients With Rheumatoid Arthritis Starting a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: 10-Year Experience From a US-Based Registry.
Matsson A, Solomon DH, Crabtree MM, Harrison RW, Litman HJ, Johansson FD. Matsson A, et al. Among authors: litman hj. ACR Open Rheumatol. 2024 Jan;6(1):5-13. doi: 10.1002/acr2.11621. Epub 2023 Oct 26. ACR Open Rheumatol. 2024. PMID: 37885052 Free PMC article.
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ, Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A. Kremer JM, et al. Among authors: litman hj. ACR Open Rheumatol. 2021 Mar;3(3):173-184. doi: 10.1002/acr2.11232. Epub 2021 Feb 11. ACR Open Rheumatol. 2021. PMID: 33570260 Free PMC article.
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.
Cohen SB, Greenberg JD, Harnett J, Madsen A, Smith TW, Gruben D, Zhang R, Lukic T, Woolcott J, Dandreo KJ, Litman HJ, Blachley T, Lenihan A, Chen C, Rivas JL, Dougados M. Cohen SB, et al. Among authors: litman hj. Adv Ther. 2021 Jan;38(1):226-248. doi: 10.1007/s12325-020-01501-z. Epub 2020 Oct 9. Adv Ther. 2021. PMID: 33034006 Free PMC article.
80 results